Real world data of ixazomib in combination with lenalidomide and dexamethasome
Factors to consider in frontline and relapsed CLL before treatment
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
Advances in monoclonal antibody therapy for multiple myeloma
Where do new drugs fit into the treatment landscape of multiple myeloma